PolyPid Ltd PYPD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
PolyPid Provides Corporate Update and Reports Third Quarter 2026 Financial Results
PolyPid to Report Third Quarter 2026 Financial Results and Operational Highlights on November 11, 2026
PolyPid Unveils Expanded Pipeline Strategy, Introducing PD01B, a New Kynatrix™ Based Product Candidate for the Treatment of Diabetic Foot Infections
PolyPid to Present D-PLEX₁₀₀ Microbiology Data at IDWeek 2026
PolyPid to Host Virtual Investor Day on Wednesday, October 28, 2026
European Medicines Agency Validates PolyPid’s Marketing Authorization Application for D-PLEX₁₀₀
PolyPid Regains European Commercialization Rights for D-PLEX₁₀₀, Expanding Global Commercialization Opportunities
PolyPid Announces Participation in Upcoming Fall Investor Conferences
Trading Information
- Previous Close Price
- $6.26
- Day Range
- $6.03–6.25
- 52-Week Range
- $3.50–7.15
- Bid/Ask
- $6.15 / $6.20
- Shares Outstanding
- 21.13M
- Market Cap
- $129.92M
- Volume/Avg
- 211,832 / 123,900
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 75
- Website
- https://www.polypid.com
Valuation
Metric | PYPD |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 33.90 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | PYPD |
|---|---|
Quick Ratio | 5.46 |
Current Ratio | 5.94 |
Interest Coverage | — |
Quick Ratio
PYPD
Profitability
Metric | PYPD |
|---|---|
Return on Assets (Normalized) | −120.51% |
Return on Equity (Normalized) | −335.58% |
Return on Invested Capital (Normalized) | −267.27% |
Return on Assets
PYPD
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|$@Ldl&@ | LOCK|F#X@ | $136B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|<%>V^# | LOCK|b!?P< | $99B | |||
| Moderna Inc MRNA | LOCK|m<#kKd | LOCK|g$s | $87B | |||
| argenx SE ADR ARGX | LOCK|m?G&&V& | LOCK|^w# | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|TV<qlq | LOCK|@^ | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|W@&J>Rn | LOCK|^FrT | $31B | |||
| Incyte Corp INCY | LOCK|bMjGV$d | LOCK|#<D | $25B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|>Rf<#Nb | LOCK|G%!Yj | $21B | |||
| BioNTech SE ADR BNTX | LOCK|d$fk>L | LOCK|F#g | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|?smjvw | LOCK|X#w | $15B |